Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10965475 | 0.98 | MMP8 (0.62) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL11228401 | 0.90 | MMP8 (0.55) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL11228384 | 0.88 | MMP8 (0.66) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL266419 | 0.87 | MMP8 (0.74) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL31069943 | 0.85 | MMP8 (0.72) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL28674585 | 0.85 | MMP8 (0.72) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL3496188 | 0.85 | MMP8 (0.51) | MMP8MEN1KMT2ANPC1TSHR | |
| SCHEMBL1275691 | 0.84 | MMP8 (0.70) | MMP8MEN1KMT2ANPC1CA12 | |
| SCHEMBL5141949 | 0.83 | MMP8 (0.45) | MMP8MEN1KMT2ANPC1TSHR | |
| SCHEMBL6959479 | 0.82 | MMP8 (0.68) | MMP8MEN1KMT2ANPC1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Ivan Aleksandrovich Starikov | 2019-04-25 | — | — | US | disclosed |
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Ivan Aleksandrovich Starikov | 2019-04-25 | — | — | US | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| EP-0768895-B1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEV CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1104397-B1 | METHOD FOR PRODUCING ATROPIC ACID ETHYL ESTER | BASF AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6509493-B1 | Method for producing atropic acid ethyl ester | KNOLL AKTIENGESELLSCHAFT (DE) | 2003-01-21 | — | — | US | disclosed |
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | NIH - DEITR | 2002-02-07 | — | — | US | disclosed |
| WO-2001080896-A2 | FLAVOPIRIDOL DRUG COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1104397-A1 | METHOD FOR PRODUCING ATROPIC ACID ETHYL ESTER | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009469-A1 | METHOD FOR PRODUCING ATROPIC ACID ETHYL ESTER | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-02-24 | — | — | WO | disclosed |
| US-5786344-A | ADMINISTERING WITH AGENT WHICH INCREASES ACTIVITY OF GLUCURONOSYLTRANSFERASE OR DECREASES ACTIVITY OF BILIARY TRANSPORT PROTEIN | ARCH DEVELOPMENT CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0768895-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001127-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | OGDH, GOT1, OAT | MMP8 4307/4885MEN1 2820/4885KMT2A 1903/4885 |
| US-20020016293-A1 | Flavopiridol drug combinations and methods with reduced side effects | UGT1A1, UGT1A3, CYP7A1 | MMP8 924/4885MEN1 4680/4885KMT2A 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.